Free tool
FAERS Monitor: Krazati
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216340 or its brand name (Krazati, Adagrasib). Reports on generic versions are filed under their own applications.
Reports
1,134
Serious
878
77% of reports
Hospitalization
423
Death reported
349
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death306
- diarrhoea133
- hospitalisation116
- nausea106
- off label use95
- vomiting90
- asthenia72
- fatigue63
- decreased appetite48
- dehydration43
- dyspnoea40
- acute kidney injury36
- renal failure33
- dizziness28
- weight decreased26
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 6 |
| 2023 | 365 |
| 2024 | 385 |
| 2025 | 201 |
| 2026 | 176 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,025 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hospitalisationSignal | 116 | 14.0 | 11.8 | 1,398 |
| deathSignal | 306 | 6.6 | 6.0 | 1,507 |
| dehydrationSignal | 43 | 6.0 | 4.5 | 174 |
| renal failureSignal | 33 | 4.6 | 3.3 | 90 |
| acute kidney injurySignal | 36 | 4.4 | 3.2 | 91 |
| decreased appetiteSignal | 48 | 3.8 | 2.9 | 99 |
| diarrhoeaSignal | 133 | 3.8 | 3.3 | 283 |
| astheniaSignal | 72 | 3.6 | 2.8 | 132 |
| vomitingSignal | 90 | 3.6 | 2.9 | 166 |
| nauseaSignal | 106 | 2.5 | 2.1 | 96 |
| off label useSignal | 95 | 2.0 | 1.7 | 49 |
| weight decreased | 26 | 1.7 | 1.2 | 7 |
| fatigue | 63 | 1.5 | 1.2 | 10 |
| dyspnoea | 40 | 1.3 | 1.0 | 3 |
| dizziness | 28 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.